Search Follow us

Pacific Edge (PEB)

Business description

Pacific Edge develops and sells a portfolio of molecular diagnostic tests based on biomarkers for the early detection and management of cancer. Tests utilising its Cxbladder technology for detecting and monitoring bladder cancer are sold in the US, New Zealand and Australia.

User programmes underway

Update | Pharmaceutical & healthcare | 14/05/2015

Pacific Edge’s bladder cancer diagnostics tests have been available in the US, New Zealand and Australia for over a year and initial sales indicate a steady ramping-up of adoption in both new customers embarking on User Programmes, as well as initial evaluations and commercial sales from existing customers. We expect news related to the conversion of these programmes into full commercial contracts in the next year. Negotiations are also well underway with key public health organisations in the US – CMS (Centers for Medicare & Medicaid Services) and the VA (Veteran’s Administration). Meanwhile, the company continues to build a world-wide patent estate around its additional genetic-based cancer diagnostic tests.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.NZ$104.9m
Last closeNZ$0.230
High / Low (52 weeks)NZ$0.5 / NZ$0.2
Stock market listingNZ
Forecast net debt (NZ$m)0.3
Forecast gearing ratio (%)189
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(28.6)(40.8)(53.4)
Relative *(30.4)(43.7)(59.6)

* % Relative to local index

Company news